Skip to main content
. 2020 Feb 20;25(5):e870–e874. doi: 10.1634/theoncologist.2019-0838

Figure 1.

Figure 1

The survival analysis of Anlotinib in different population. (A): Progression‐free survival for patients with brain metastases (BM) at baseline. (B): Overall survival for patients with BM at baseline. (C): Progression‐free survival for patients without BM at baseline. (D): Overall survival for patients without BM at baseline. (E): Kaplan‐Meier estimates of time to brain progression. (F): Subgroup analysis for time to brain progression.Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, endothelial growth factor receptor; HR, hazard ratio; TKI, tyrosine kinase inhibitor.